Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jan 9 2018 report suggests Marqibo to largely impact market in 2020
http://www.military-technologies.net/2018/01/09/acute-lymphocyticlymphoblastic-leukemia-therapeutics-market-pipeline-forecast-market-forecast-in-g8-countries-2011-2020/
In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.).
I originally hoped 2018 would see the first milestone payment reached but the past sales do not show a clear rising trend to meet it.
I am pleased to hear there are possibilities to expand the use of marqibo that may accelerate future milestones:
http://www.futurity.org/chemotherapy-nanodrugs-intralipid-1621152/
Would you happen to know when we can expect to get something out of holding this CVR for almost 5 years now?
CVR "Talon.CR" Payment? When can we expect to get paid for the first time with Talon CVR? I've been waiting for years like many of you. Just wondering if we can expect something in 2018.
Thank you!
Possible new technique to assist opening market for Marqibo
https://www.sciencedaily.com/releases/2017/11/171128160310.htm
https://scicasts.com/channels/nanotechnology/1863-nanomedicine/13060-new-technique-developed-that-reduces-side-effects-improves-delivery-of-chemotherapy-nanodrugs/
https://www.nature.com/articles/s41598-017-16293-6
Li Liu, Qing Ye, Maggie Lu, Shih-Ta Chen, Hsiang-Wen Tseng, Ya-Chin Lo, Chien Ho. A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid. Scientific Reports, 2017; 7 (1) DOI: 10.1038/s41598-017-16293-6
we need higher revenues through market expansion
https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-238-million-registered-direct-offering-led-by-existing-shareholders-300536401.html
I am not sure which website is correct on the timeline: 4-6 weeks or months but probably the latter?
http://stocknewsunion.com/8476-2/8476/
"agency is also reviewing an application for approval of MARQIBO for the treatment of adult patients with Philadelphia chromosome negative lymphoblastic leukemia. A review of the drug is set to be complete in the next four to six weeks."
https://seekingalpha.com/news/3294112-casi-provides-pipeline-development-update
The CFDA review of MARQIBO and CTA is in process. Its review is expected to complete in the next four to six months and confirmatory trial will initiate within six months after CTA approval.
Anyone hear anything about revenues on Marquibo? Any news on Tlon pipelines? We have lost everything?
what are new with the sppi thiefs.... share are near ATH and nothing for us ??
we got any positive news?? I hope they increase more sales for Marquibo with better global marketing strategies...and more excellent results for efficacies of going trials
Two MARQIBO related abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017
http://www.satprnews.com/2017/06/02/spectrum-pharmaceuticals-highlights-three-abstracts-of-clinical-data-at-the-2017-american-society-of-clinical-oncology-asco-annual-meeting-in-chicago-illinois-june-2-6-2017-2/
Ongoing Study: Marqibo in combination with UK ALL R3
https://clinicaltrials.gov/ct2/show/NCT02879643
Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium
Collaborator:
Spectrum Pharmaceuticals, Inc
Study Start Date: July 2016
Estimated Study Completion Date: March 2019
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)
Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results
May 2 2017
http://investor.sppirx.com/releasedetail.cfm?ReleaseID=1024058
MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $2.0 million
I think more tham 7 mil revenues for Marqibo we can see it from sppi annual report! We need at least $30 mil annual revenues to get paid for each CVR ? Please we all can check it !
I think more tham 7 mil revenues for Marqibo we can see it from sppi annual report! We need at least $30 mil annual revenues to get paid for each CVR ? Please we all can check it !
Hey I am waiting as well if you know something please post that information. Thk
Anyone know how much for total revenues for Tlon ? How much total revenues we will have for 2016? For Tlon shareholders?
taken from q3 2016 SPPI:
Fair Value
of Talon
CVR
December 31, 2015
$
1,377
Fair value adjustment for the nine months ended September 30, 2016
476
September 30, 2016
$
1,853
that means:1,853 million$ worth all cvr's per 09/30/16
they not pay quarterly CVRs? or annual payouts only? at least at how much for quarterly or annual net sales will generate CVRs payout? how long CVRs will be valid for common shareholders?
we hope and need good lucks for better clinical trials and new treatments from Marqibo for sick patients around the globe
No choice but to wait...I suspect annual CVR payouts are possible starting in a couple of years:
Some reasons:
1. https://www.ncbi.nlm.nih.gov/pubmed/27328933
vincristine is slowly released from the liposome and delivered into the tissues more efficiently than with the standard preparation, allowing a higher dose. This increase in therapeutic index from reduced toxicity is a valuable difference between the two formulations."
"Clinicians will be informed of a new chemotherapy agent that is indicated for the treatment of adults with Philadelphia chromosome-negative acute lymphoblastic leukemia, whose disease has relapsed two or more times or whose leukemia has progressed after two or more regimens of antileukemia therapy."
2. http://www.thno.org/v06p1306.htm
3. Sales growth potential in China
http://www.prnewswire.com/news-releases/casi-pharmaceuticals-import-drug-registration-application-for-marqibo-accepted-for-review-by-cfda-300202705.html
CASI just reported expenditure on samples for the CFDA
"Our research and development expenses for the second quarter increased over the prior year due to costs associated with purchasing MARQIBO® samples required for our China import product drug application"
http://finance.yahoo.com/news/casi-pharmaceuticals-reports-second-quarter-110000670.html
How much at least Marqibo net sale...so we common shareholders can get some money for our CVRs each quarter?each year?....how long TLON CVRs ( for preferred and common shareholders) will be valid until what time?
anyone know something? please post it...Thanks
Q2 2016 sales flat: MARQIBO® net sales of $2.1 million
http://www.businesswire.com/news/home/20160809006282/en/Spectrum-Pharmaceuticals-Reports-Quarter-2016-Financial-Results
http://www.nasdaq.com/article/spectrum-sppi-incurs-narrower-than-expected-loss-in-q4-cm591425
Marqibo sales surged 107.7% sequentially to $2.7 million. This puts Marqibo quarterly sales at 37% of the first milestone target if this sales level was sustained over any year.
Last quarter was hopefully an outlier at $1.3 million. The quarter before that was $2.1 million so the long term trend is up.
Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results Teleconference and Webcast
Mar 02, 2016 07:00:00 (ET)
HENDERSON, Nev.--(BUSINESS WIRE)--March 02, 2016--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to discuss the fourth quarter and full year 2015 financial results, provide an update on the Company's business, and discuss expectations for the future.
Conference Call
MARQUIBO REVENUE INFO
Wednesday, March 9, 2016 @ 4:30 p.m. Eastern/1:30 p.m. Pacific
------------------------------------------------------------------------------
Domestic: (877) 837-3910, Conference ID# 51999726
International: (973) 796-5077, Conference ID# 51999726
For interested individuals unable to join the call, a replay will be available from March 9, 2016 @ 7:30 p.m. ET/4:30 p.m. PT through March 19, 2016 until 11:59 p.m. ET/8:59 p.m. PT.
Domestic Replay Dial-In (855) 859-2056, Conference ID# 51999726
#:
International Replay (404) 537-3406, Conference ID# 51999726
Dial-In #:
This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals' website: www.sppirx.com on March 9, 2016 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results Teleconference and Webcast
Mar 02, 2016 07:00:00 (ET)
HENDERSON, Nev.--(BUSINESS WIRE)--March 02, 2016--
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to discuss the fourth quarter and full year 2015 financial results, provide an update on the Company's business, and discuss expectations for the future.
Conference Call
MARQUIBO REVENUE INFO ON MARCH 9 ,16 CONFERENCE?
Wednesday, March 9, 2016 @ 4:30 p.m. Eastern/1:30 p.m. Pacific
------------------------------------------------------------------------------
Domestic: (877) 837-3910, Conference ID# 51999726
International: (973) 796-5077, Conference ID# 51999726
For interested individuals unable to join the call, a replay will be available from March 9, 2016 @ 7:30 p.m. ET/4:30 p.m. PT through March 19, 2016 until 11:59 p.m. ET/8:59 p.m. PT.
Domestic Replay Dial-In (855) 859-2056, Conference ID# 51999726
#:
International Replay (404) 537-3406, Conference ID# 51999726
Dial-In #:
This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals' website: www.sppirx.com on March 9, 2016 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
Any TLON Investor hear/know any value for our CVRs for any quarter from last year? please post.Thanks
Good news for Marqibo. Merry Christmas n Happy New Years
http://www.kait8.com/story/30714091/marqibo-made-available-to-acute-lymphoblastic-leukemia-patients-through-global-mytomorrows-platform
http://prnewswire-yahoopartner.tumblr.com/post/134918357821/marqibo-made-available-to-acute-lymphoblastic
http://biz.yahoo.com/n/y/y0005.html?id=94730910
http://www.abcnews4.com/category/48859/biotechnology
http://www.keyc.com/category/48529/medicine-pharmaceuticals
http://www.evaluategroup.com/Universal/View.aspx?type=Report&id={17487AD5-A6F8-4764-98F9-A587CE69719B}¶ms=%3CPARAMS%20currencyId=%220%22%3E%3CPARAM%20linkKind=%220%22%20compId=%22co_1%22%20itemId=%22c31000900%22%20/%3E%3C/PARAMS%3E&more=true
http://www.businesswire.com/news/home/20151204005117/en/Spectrum-Pharmaceuticals-Highlights-18-Abstracts-57th-Annual
The following are key Marqibo® (vinCRIStine sulfate LIPOSOME injection) related abstracts being presented at the ASH meeting:
Abstract # Type Title First Author Location
1291 Poster Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population Schiller Saturday, Dec 5,
5:30 PM-7:30 PM
Hall A, Level 2
2491 Poster Plasma Vincristine Levels Are 100-Fold Higher with Marqibo®(Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Wang Sunday, Dec 6,
6:00 PM-8:00 PM
Hall A, Level 2
3965 Poster The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies Ahmed Monday, Dec 7,
6:00 PM-8:00 PM
Hall A, Level 2
3720 Poster Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial Sasaki Monday, Dec 7,
6:00 PM-8:00 PM
Hall A, Level 2
http://www.businesswire.com/news/home/20151104006550/en/Spectrum-Pharmaceuticals-Reports-Quarter-2015-Financial-Results
That is a big decrease from $2.1million in the previous quarter to $1.3million just released. It is the laggard in the product sales list. We have a long way to go!
SPECTRUM FINANCIAL REPORT 3TH QUARTER ON NOV 4,2015 4.30 ET
http://www.morningstar.com/news/business-wire/BWIPREM_20151102005360/spectrum-pharmaceuticals-announces-third-quarter-2015-financial-results-teleconference-and-webcast.html
Thanks for digging this up. Yes, it is probably 20 years unless the Menadione patent expires first. Need a legal expert to decipher this!
6.8 Termination. Any liability of Parent and its successors and or assigns with respect to, and the obligation to pay, any Milestone Amounts, other than the Regulatory Milestone, or any directly related payments pursuant to this Agreement shall be terminated and of no force or effect upon the date that is 20 years after the date of this Agreement. Any liability of Parent and its successors and or assigns with respect to, and the obligation to pay, the Regulatory Milestone Amount or any directly related payments pursuant to this Agreement, shall be terminated and of no force or effect upon the expiration of the Menadione Patent Rights. This Agreement shall otherwise be terminated and of no force or effect and the parties hereto shall have no liability hereunder upon the later to occur of: (i) the date that is 20 years after the date of this Agreement; or (ii) the expiration of the Menadione Patent Rights
some son said CVRs will become expired in 20yrs, see section 6.8...????
http://www.sec.gov/Archives/edgar/data/831547/000119312513295701/d568990dex23.htm
What you all think about it????
There appears to be no expiry date because each milestone condition has: "in any calendar year" or "upon receipt of marketing authorization from the FDA". There is no expiry mentioned.
http://www.sec.gov/Archives/edgar/data/831547/000119312513445708/R21.htm
I do not know how long our CVRs will become expired from the date of Purchase Agreement ( July 17, 2013?),
and under what conditions? please share?
I hope doctors, hospitals, clinics.,medical centers.. around the globe will prescribe and use Marqibo more instead of other drugs for the same treatment..so we will hit many milestones quicker...God bless TLON Shareholders and patients need the drug for their better health from their treatment
Thanks for confirming the number of CVRs issued. I think the first milestone will be underwhelming. I am more interested to see if this can hit the higher levels.
Below are published studies from 2014 that could help towards an expanded label of Marqibo.
http://www.ncbi.nlm.nih.gov/pubmed/24252360
http://www.ncbi.nlm.nih.gov/pubmed/24417913
The last publication is particularly interesting and the main reason I invested in Talon Pharmaceuticals.
It was mentioned this month (first in the list of similar substances) in the "Expert Review of Anticancer Therapy"
http://www.ncbi.nlm.nih.gov/pubmed/26402250
Also, CASI Pharmaceuticals may show sales growth of Marqibo in China but I guess these would feed into Spectrums's numbers.
TLON has total 201380780 CVRs, if we hit any milestone, it will divide by total CVRs ....God bless TLON shareholders...
Each CVR holder(or their broker) is either on a CVR register with Corporate Stock Transfer Inc or another agent.
http://www.dailyfinance.com/2013/07/17/spectrum-pharmaceuticals-acquires-talon-therapeuti/
My concern is not where they are since they cannot be traded but how far off away the current sales level is from even the first milestone payment. Milestone payments for the CVRs are detailed here:
http://www.sec.gov/Archives/edgar/data/831547/000119312513445708/R21.htm
Given this payment schedule and ongoing clinical trials for Marqibo, it is unlikely any payments can occur soon. The following article suggests the first milestone is reached in 2018 according to the author's sales model.
http://www.thestreet.com/story/11989128/1/spectrum-can-generate-profits-from-misfit-cancer-drugs.html
I cannot remember how many CVRs were issued but if anyone has the figure off-hand, then you can work out a single CVR payment for the $5million payment. I am not throwing my CVRs away but not counting on getting my investment back. On the other hand, I have not been following the Marqibo R&D investments by Spectrum as the author suggests to see if there is more potential here. All we can do is wait otherwise.
The Spectrum report on Aug 6th shows Marqibo quarterly sales at 28% of the first milestone target if this sales level was sustained over any year:
MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $2.1 million
http://investor.sppirx.com/releases.cfm
If anyone sees potential in Marqibo developments, please share.
We can call Spectrum Pharma investor relations at 949-788-6700 to ask them about our CVR?
Any other phone or who from Spectrum can help us about our CVR? our lawyers?
so we TLON Shareholders get how much from this revenue of Marqibo?
God bless TLON shareholders!
revenue marqibo 1.Q 2015 1.9 million vs 1.5 in 2014
see SPPI data from 05/08/2015 1.Quarter numbers
THREE MONTHS ENDED MARCH 31, 2015 VERSUS 2014
Total Revenues
Three months ended March 31,
2015 2014 $ Change % Change
($ in millions)
Product sales, net:
FUSILEV $ 20.2 $ 22.2 $ (2.0 ) (9.0 )%
FOLOTYN 9.3 10.1 (0.8 ) (7.9 )%
ZEVALIN 4.2 6.3 (2.1 ) (33.3 )%
MARQIBO 1.9 1.5 0.4 26.7 %
BELEODAQ 2.8 - 2.8 - %
$ 38.4 $ 40.1 $ (1.7 ) (4.2 )%
License fees and service revenue 0.2 - 0.2 - %
Total revenues $ 38.6 $ 40.1 $ (1.5 ) (3.7 )%
Still waiting for some Miracle.
We are TLON Shareholders not receive anything from SPECTRUM?
SPECTRUM PHARMACEUTICALS, INC.
157 Technology Drive
Irvine, CA 92618
TEL: 949-743-9239
I dont envision ever getting money back for the cvr. My guess is that the bailout maximized profit because only certain technologies were needed for other drugs. I havent read the terms of the cvr in a couple years but i think we are done. If the sec didnt say this is wrong, i would say there is nothing we can do.
Any one hears anything from Spectrum about TLON CVR? I contact my lawyers about this?
We TLON haven't received any penny or dime from SPECTRUM yet? anyone hear /see any reports from SPECTRUM? God please help TLON shareholders!
anyone knows or hears anything about TLON DRUG PIPELINES REVENUES from SPECTRUM?
Followers
|
91
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6072
|
Created
|
05/02/06
|
Type
|
Free
|
Moderators |
Talon Therapeutics, Inc. is a San Francisco Bay Area-based biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
Talon Therapeutics, Inc.
2207 Bridgepointe Parkway
Suite 250
San Mateo, CA 94404
United States - http://maps.yahoo.com/maps_result?addr=2207%20Bridgepointe%20Parkway%20Suite%20250&csz=San%20Mateo%20CA%2094404&country=United%20States" rel="nofollow">Map
Phone: 650-588-6404
Fax: 650-588-2787
Website: http://www.talontx.com
Business Summary |
---|
Talon Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. Its lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate, which is in the development for the treatment of adult acute lymphoblastic leukemia. The company's product candidates also include Menadione Topical Lotion, a supportive care product candidate that completed Phase 1 clinical trial for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, a type of anti-cancer agent used in the treatment of lung, colon, head and neck, pancreatic, and breast cancer; and Brakiva (topotecan liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of metastatic carcinoma of the ovary and small cell lung cancer. In addition, its development stage product consists of Alocrest (vinorelbine liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, such as non-small-cell lung cancer. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. The company was formerly known as Hana Biosciences, Inc. and changed its name to Talon Therapeutics, Inc. in December 2010. Talon Therapeutics, Inc. was founded in 2002 and is based in San Mateo, California
Current Pipeline
Marqibo® (vincristine sulfate liposomes injection, OPTISOME™)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin's lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma. More Details »
Alocrest™ (vinorelbine liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity. More Details »
Brakiva™ (topotecan liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan. More Details »
Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor. More Details »
Presentations | ||||
---|---|---|---|---|
Talon Therapeutics Corporate Presentation | 869.6 KB |
INFOS
Steven R. Deitcher , MD
President & Chief Executive Officer
Craig W. Carlson
Senior Vice President, Chief Financial Officer
Gradon D. Knotts
Vice President, Business Development
Nandan Oza
Vice President, Chemistry, Manufacturing, and Controls
Thomas J. Tarlow
Vice President, Regulatory Affairs and Quality
Steven R. Deitcher, M.D.
President & Chief Executive Officer
Nishan de Silva, M.D.
Principal, Warburg Pincus
Andrew K. Ferrer
Associate, Warburg Pincus
Howard P. Furst, M.D.
Partner, Deerfield Management
Jonathan S. Leff
Managing Director, Warburg Pincus
Paul V. Maier
Chief Financial Officer, Sequenom, Inc.
Leon E. Rosenberg, M.D. (Chairman)
Professor of Molecular Biology, Princeton University
Robert J. Spiegel, M.D.
Director
Current Share Structure
Current as of 12/31/2010
A/S 350,000,000
O/S 21,242,772 (Mar 28, 2011)
FLOAT 16.48M
Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, CO 80209
Recent news
Charting
New presentation from tlon from 3-30-12
http://files.shareholder.com/downloads/HNAB/1722627662x0x556820/A59F1E05-C4F6-4235-B039-7B3CCE775B48/talontx_corp_pres.pdf
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |